Manjili M H, Wang X Y, Park J, Macdonald I J, Li Y, Van Schie R C A A, Subjeck J R
Department of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Int J Hyperthermia. 2002 Nov-Dec;18(6):506-20. doi: 10.1080/02656730110116696.
Heat shock proteins (hsps) can induce anti-cancer immune responses by targeting associated tumour antigens to the immune system. Hsps are not merely carriers of antigen but can also induce maturation of dendritic cells (DCs), resulting in a more efficient antigen presentation. However, improvement of hsp-based vaccines is still desirable if one is to realize their full therapeutic potential. Since the immune system consists of different elements functioning together in a highly integrated way, a combination therapy utilizing important immunomodulators together with hsp-based vaccination may improve therapeutic response. Hyperthermia has been shown to have important stimulatory effects on several cellular and organismal endpoints related to the immune system. This review highlights advantages and disadvantages of various ways of using stress proteins in cancer immunotherapy. It also overviews the interaction of hyperthermia with heat shock protein therapy and the related effects on the host's immune response.
热休克蛋白（hsps）可通过将相关肿瘤抗原靶向免疫系统来诱导抗癌免疫反应。热休克蛋白不仅是抗原的载体，还能诱导树突状细胞（DCs）成熟，从而实现更高效的抗原呈递。然而，若要充分发挥基于热休克蛋白的疫苗的治疗潜力，仍需对其进行改进。由于免疫系统由以高度整合方式共同发挥作用的不同成分组成，将重要的免疫调节剂与基于热休克蛋白的疫苗接种相结合的联合疗法可能会改善治疗反应。热疗已被证明对与免疫系统相关的几个细胞和机体终点具有重要的刺激作用。本综述重点介绍了在癌症免疫治疗中使用应激蛋白的各种方法的优缺点。它还概述了热疗与热休克蛋白疗法的相互作用以及对宿主免疫反应的相关影响。
